Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Catriona HarveyKazi J NaharJanet McKeownSerigne N LôSheima FaragNadia YousafKate YoungLiselotte TasAafke Meerveld-EgginkChristian BlankAustin ThomasJennifer McQuadeBastian SchillingDouglas B JohnsonRoberto Martín HuertasAna AranceJoanna LeeLisa ZimmerGeorgina V LongMatteo S CarlinoYinghong WangAlexander Maxwell MenziesPublished in: Journal for immunotherapy of cancer (2024)
IRIGItox causes major morbidity and mortality. Management is heterogeneous. CNIs appear most likely to result in toxicity resolution in the shortest time period, however, are associated with poorer oncological outcomes in contrast to vedolizumab.